Keyphrases
Atropine
7%
Autonomic Function
7%
Capillary
24%
Carbon Encapsulation
75%
Carboxylated multi-walled Carbon Nanotubes
75%
Cell Apoptosis
7%
Chick
37%
Chiral Selector
75%
Chiral Separation
24%
Clinical Application
7%
Clinically Significant
37%
Consecutive Days
18%
Corneal Curvature
7%
Dopamine
18%
Dopamine System
18%
Dopaminergic System
18%
Dose Effect
7%
Dysregulated
18%
Dysregulation
18%
Electroretinogram
7%
Enantioselectivity
24%
Enantioseparation
75%
End of Treatment
18%
Experimental Myopia
15%
Eye Drops
56%
Fellow Eye
18%
Form-deprivation Myopia
22%
Frequency Doubling Perimetry
18%
Functionalized multi-walled Carbon Nanotubes
24%
Group-oriented Applications
7%
Healthy Males
18%
High Dose
18%
High-performance Liquid Chromatography
75%
HPLC Separation
24%
Intraocular Pressure
7%
Intravitreal Injection
22%
Lens Thickness
7%
Lens-induced Myopia
15%
Levodopa
75%
Levodopa-carbidopa
56%
Lipase
75%
Lipase Immobilization
24%
Monolith
24%
Monolithic Capillary Column
75%
Monolithic Polymer
24%
Multi-walled Carbon Nanotubes (MWCNTs)
75%
Multifocal Electroretinogram (mfERG)
37%
Myopia
18%
NanoLC
50%
Nicotine
75%
Nicotinic Receptors
7%
Normal Vision
18%
Normal-phase HPLC
24%
Ocular Disorders
37%
Ocular Growth
15%
Ocular Health
7%
Ocular Safety
7%
Older Adults
75%
Optical Coherence Tomography
18%
Organic Polymer
75%
Pharmacokinetic Analysis
18%
Phase I Trial
18%
Placebo
18%
Pupillary Reflex
7%
Racemic
75%
Racemic Drugs
24%
Regional Analysis
18%
Regional Frequency
18%
Retinal Function
82%
Retinal Health
7%
Retinal Structure
37%
Retinal Thickness
26%
Retinal Thickness Map
18%
Retinal Thinning
18%
Reversed-phase HPLC
24%
Short-term Use
18%
Temporary Reduction
7%
Therapeutic Solutions
18%
Topical Application
82%
Topical Eye Drops
15%
Topical Treatment
7%
Translational Relevance
18%
Visual Acuity
18%
Medicine and Dentistry
Autonomic Function
24%
Carbidopa/Levodopa
56%
Cardiorespiratory
24%
Dopaminergic System
18%
Drug Megadose
18%
Eye Disease
37%
Intraocular Pressure
24%
Intravitreal Administration
75%
Levodopa
75%
Low Drug Dose
56%
Nicotinic Receptor
24%
Optical Coherence Tomography
18%
Pharmacokinetic
18%
Phase I Trials
18%
Placebo
18%
Programmed Cell Death
24%
Pupillary Reflex
24%
Side Effect
24%
Topical Drug Administration
100%
Topical Treatment
24%
Visual Acuity
18%
Visual Field Test
18%